BOSUTINIB TEVA 400mg film-coated tablets medication leaflet

L01EA04 • bosutinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors

Bosutinibum is a medication used for the treatment of chronic myeloid leukemia (CML) in adult patients with BCR-ABL gene mutations. It is a tyrosine kinase inhibitor that blocks the abnormal activity of the BCR-ABL protein, which drives the uncontrolled growth of leukemic cells.

The medication is taken orally, usually once daily, as directed by a doctor. The dosage may be adjusted based on the patient's response and tolerance to treatment.

Common side effects include nausea, diarrhea, vomiting, fatigue, and elevated liver enzyme levels. In rare cases, more severe adverse effects such as liver toxicity or fluid retention may occur.

Bosutinibum is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.